Doctor’s Letter Triggers Pioglitazone Ban; India’s Health Ministry Under Fire
This article was originally published in PharmAsia News
The waffling of India’s drug regulatory agency on the pioglitazone ban reveals cracks in the regulatory system.
You may also be interested in...
Withdrawals call into question the remaining revenues the diabetes product can generate before its main patents expire.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.